公开(公告)号：US12076301B2

公开(公告)日：2024-09-03

申请号：US17407043

申请日：2021-08-19

申请人： The Regents of the University of California

发明人： Daniel C. Lu ,  V. Reggie Edgerton ,  Roland R. Roy ,  Yury P. Gerasimenko

IPC分类号： A61K31/137 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/527 ,  A61N1/05 ,  A61N1/36

CPC分类号： A61K31/137 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/527 ,  A61N1/0551 ,  A61N1/36003 ,  A61N1/36034 ,  A61N1/36067 ,  A61N1/36171

摘要： In various embodiments, methods are provided for applying transcutaneous and/or epidural spinal cord stimulation with and without selective pharmaceuticals to restore voluntary control of hand function in tetraplegic subjects.

公开(公告)号：US20230381307A1

公开(公告)日：2023-11-30

申请号：US18363404

申请日：2023-08-01

申请人： Richard Louis Price

发明人： Richard Louis Price

IPC分类号： A61K39/395 ,  A23L3/3553 ,  C07F9/117 ,  A61K31/4168 ,  A61K31/155 ,  A61K31/165 ,  A61K9/00 ,  A61K31/047 ,  A61K45/06 ,  A61J1/00

CPC分类号： A61K39/395 ,  A23L3/3553 ,  C07F9/117 ,  A61K31/4168 ,  A61K31/155 ,  A61K31/165 ,  A61K9/0004 ,  A61K31/047 ,  A61K45/06 ,  A61J1/00 ,  A61K2039/545

摘要： Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

公开(公告)号：US20230256161A9

公开(公告)日：2023-08-17

申请号：US17141876

申请日：2021-01-05

申请人： Palo Alto Investors LP

发明人： Anthony Joonkyoo Yun ,  Patrick Yuarn-Bor Lee

IPC分类号： A61M5/142 ,  A61N1/36 ,  A61K31/395 ,  A61K31/4168 ,  A61K31/4188 ,  A61K31/475

CPC分类号： A61M5/14276 ,  A61N1/3605 ,  A61N1/36117 ,  A61K31/395 ,  A61K31/4168 ,  A61K31/4188 ,  A61K31/475 ,  A61M2205/054 ,  A61N1/36002 ,  A61N1/05

摘要： Methods for treating a disease condition in a subject are provided. The subject methods are characterizing by enhancing at least one symptom of the disease condition in a manner effective to cause the subject to mount a compensatory response effective to treat the disease condition. Also provided are compositions, kits and systems for practicing the subject methods.

公开(公告)号：US11654134B2

公开(公告)日：2023-05-23

申请号：US16948235

申请日：2020-09-09

申请人： Nour Heart, Inc.

发明人： Salwa A. Elgebaly

IPC分类号： C07H21/02 ,  C07H21/04 ,  A61K31/4168 ,  G01N33/68 ,  A61K31/137 ,  A61K9/00

CPC分类号： A61K31/4168 ,  A61K31/137 ,  G01N33/6893 ,  A61K9/0019

摘要： The present invention provides methods and composition of a novel mechanism using the bioenergetic Cyclocreatine Phosphate as a potent cardioprotective drug by preserving cellular energy source, preventing ischemic injury, rejuvenating organ function, thus, maintaining normal physical activity. Cyclocreatine Phosphate can be used as a new therapeutic approach to prevent disease development and progression, and to treat ischemia-induced diseases in ischemic heart disease patients, including: coronary artery disease, unstable angina, acute myocardial infarction, heart failure, atrial fibrillation, and Takotsubo cardiomyopathy, as well as provides cardioprotection during cardiac procedures and surgeries. The invention further provides methods and composition to prevent and treat aging-related neurodegenerative diseases where hypoxia/ischemia play a key role in the development and progression of the disease. More specifically, the present invention provides Cyclocreatine Phosphate as a new therapeutic approach to prevent disease development and progression, as well as to treat patients with brain ischemia (stroke) and Alzheimer's disease.

公开(公告)号：US20190194181A1

公开(公告)日：2019-06-27

申请号：US16292524

申请日：2019-03-05

申请人： vTv Therapeutics LLC

发明人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Jareer Nabeel Kassis ,  Matthew J. Kostura ,  Mustafa Guzel ,  Otis Clinton Attucks ,  Robert Carl Andrews ,  Samuel Victory ,  Suparna Gupta

IPC分类号： C07D417/12 ,  C07D513/04 ,  C07D235/30 ,  A61K31/437 ,  C07D417/14 ,  A61K31/4188 ,  A61K31/4168 ,  C07D471/04 ,  A61K31/428

CPC分类号： C07D417/12 ,  A61K31/4168 ,  A61K31/4188 ,  A61K31/428 ,  A61K31/437 ,  C07D235/30 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

摘要： Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating conditions or diseases of the eye are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.

公开(公告)号：US20180250255A1

公开(公告)日：2018-09-06

申请号：US15979730

申请日：2018-05-15

申请人： Vireo Systems, Inc.

发明人： Thomas McDonald ,  Kristen Drescher

IPC分类号： A61K31/198 ,  A61K9/00 ,  A61K31/417 ,  A61K31/4168

CPC分类号： A61K31/198 ,  A61K9/0014 ,  A61K31/4168 ,  A61K31/417

摘要： The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.

公开(公告)号：US20180221297A1

公开(公告)日：2018-08-09

申请号：US15887345

申请日：2018-02-02

申请人： Kirti H. Valia

发明人： Kirti H. Valia

IPC分类号： A61K9/70 ,  A61K9/00 ,  A61K31/4468 ,  A61K31/4168 ,  B32B38/10 ,  B32B37/12 ,  B32B37/10 ,  B32B37/18 ,  B32B37/20 ,  B32B7/12 ,  B32B27/08 ,  B32B27/30 ,  B32B27/36

CPC分类号： A61K9/7038 ,  A61K9/0014 ,  A61K9/703 ,  A61K9/7053 ,  A61K9/7061 ,  A61K9/7084 ,  A61K31/4168 ,  A61K31/4468 ,  B32B7/12 ,  B32B27/08 ,  B32B27/306 ,  B32B27/308 ,  B32B27/36 ,  B32B37/10 ,  B32B37/1207 ,  B32B37/182 ,  B32B37/203 ,  B32B38/10 ,  B32B2038/045 ,  B32B2305/72 ,  B32B2331/04 ,  B32B2333/00 ,  B32B2367/00 ,  B32B2556/00

摘要： Transdermal drug delivery devices and systems with improved adhesion are disclosed. The transdermal drug delivery devices, or patches, include an integrated overlay that provides a drug-free adhesive perimeter designed to avoid affecting delivery of drug from the device. Also disclosed are methods of manufacturing the transdermal drug delivery devices that include incorporating an integrated overlay onto a TDS patch.

公开(公告)号：US20180185375A1

公开(公告)日：2018-07-05

申请号：US15739005

申请日：2016-06-22

申请人： EMBERA NEUROTHERAPEUTICS, INC.

发明人： Michael Detke ,  Martin Phillips ,  Robert Linke

IPC分类号： A61K31/53 ,  A61K31/519 ,  A61K31/4196 ,  A61K31/4188 ,  A61K31/343 ,  A61K31/138 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4168 ,  A61P25/30

CPC分类号： A61K31/53 ,  A61K31/138 ,  A61K31/343 ,  A61K31/4168 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  A61P25/30 ,  A61K2300/00

摘要： The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the HPA axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription medication (e.g., Percodan®, Percoset®), marijuana, tobacco, methadone, food), addiction to an activity (e.g., gambling, sex, eating), substance use disorders, mood disorders, anxiety disorders, bipolar disorder, sleep disorders, insomnia, posttraumatic stress syndrome, borderline personality disorder, disruptive behavior disorders, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, eating disorders (e.g., Prader Willi Syndrome), obesity, depression, menopause, premenstrual syndrome (PMS), obsessive compulsive disorder (OCD), social anxiety, generalized anxiety disorder, dysthymia, or schizophrenia.

公开(公告)号：US20180169064A1

公开(公告)日：2018-06-21

申请号：US15736285

申请日：2016-06-23

申请人： Threshold Pharmaceuticals, Inc.

发明人： Mark Matteucci ,  Xiaohong Cai ,  Yeyu Cao ,  Hailong Jiao ,  Jing Yuan Ma ,  Jian-Xin Duan

IPC分类号： A61K31/396 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/665 ,  A61K31/675 ,  A61P35/00

CPC分类号： A61K31/396 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/665 ,  A61K31/675 ,  A61P35/00 ,  C07F9/564 ,  C07F9/65583 ,  C07F9/65586 ,  C07F9/6561

摘要： Provided herein are compounds of formula (I)-(VI), wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

公开(公告)号：US09993452B2

公开(公告)日：2018-06-12

申请号：US14960806

申请日：2015-12-07

申请人： Vireo Systems, Inc.

发明人： Thomas McDonald ,  Kristen Drescher

IPC分类号： A61K31/415 ,  A61K31/19 ,  A61K31/198 ,  A61K9/00 ,  A61K31/4168 ,  A61K31/417

CPC分类号： A61K31/198 ,  A61K9/0014 ,  A61K31/4168 ,  A61K31/417

摘要： The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.